To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

IL-1 receptor antagonist improves knee function of acute knee injuries with an ACL tear

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
August 2013

IL-1 receptor antagonist improves knee function of acute knee injuries with an ACL tear

Vol: 2| Issue: 7| Number:414| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254).

Osteoarthritis Cartilage. 2012 Apr;20(4):271-8. Epub 2012 Jan 10

Contributing Authors:
VB Kraus J Birmingham TV Stabler S Feng DC Taylor Moorman CT WE Garrett AP Toth

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

11 patients with acute knee injuries, occurring within 30 days of evaluation and presenting with an ACL tear, were randomized to receive an intraarticular injection with an IL-1 receptor antagonist (IL-1Ra) or saline. Authors hypothesized that injection with IL-1Ra would improve KOOS pain and functional scores over a 2 week follow-up period prior to operative reconstruction. Results indicated that...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue